Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-10-01 DOI:10.21873/anticanres.17803

Kyosuke Nishio, Kensuke Hirosuna, Taizo Uchimoto, Heima Niigawa, Sho Kakumae, Taisuke Jo, Hirofumi Morinaka, Wataru Fukuokaya, Atsuhiko Yoshizawa, Masanobu Saruta, Mamoru Hashimoto, Takafumi Minami, Yutaka Yamamoto, Moritoshi Sakamoto, Kazuki Nishimura, Ryoichi Maenosono, Takuya Tsujino, Yuki Yoshikawa, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Kazutoshi Fujita, Takahiro Kimura, Haruhito Azuma, Kazumasa Komura

{"title":"Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.","authors":"Kyosuke Nishio, Kensuke Hirosuna, Taizo Uchimoto, Heima Niigawa, Sho Kakumae, Taisuke Jo, Hirofumi Morinaka, Wataru Fukuokaya, Atsuhiko Yoshizawa, Masanobu Saruta, Mamoru Hashimoto, Takafumi Minami, Yutaka Yamamoto, Moritoshi Sakamoto, Kazuki Nishimura, Ryoichi Maenosono, Takuya Tsujino, Yuki Yoshikawa, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Kazutoshi Fujita, Takahiro Kimura, Haruhito Azuma, Kazumasa Komura","doi":"10.21873/anticanres.17803","DOIUrl":null,"url":null,"abstract":"Background/aim: Enfortumab vedotin (EV) is an antibody-drug conjugate approved for metastatic urothelial carcinoma (mUC); however, clinical data in elderly patients are limited. Given the increasing use of EV as a first-line or subsequent treatment, assessing its safety and efficacy in older populations is crucial.Patients and methods: This retrospective, multi-institutional study evaluated the safety and efficacy of EV in patients aged ≥80 years with platinum-refractory mUC. Clinical outcomes were compared with those in patients aged <80 years. Propensity score matching (PSM) was used to minimize selection bias.Results: Among 129 patients included, 25 (19%) were aged ≥80 years. Median follow-up was 7.7 months. There were no significant differences in overall survival (OS: 14.7 vs. 8.9 months, p=0.411), progression-free survival (PFS: 10.2 vs. 6.5 months, p=0.972), or objective response rate (ORR: 56% vs. 46%, p=0.248) between older and younger patients. Rates of treatment discontinuation and dose reduction were comparable between patients aged ≥80 and those aged <80 years, with no statistically significant differences (8% vs. 13%, p=0.529; 28% vs. 21%, p=0.438).Conclusion: EV demonstrated comparable efficacy and tolerability in patients aged ≥80 years relative to younger counterparts. These findings support the safe and effective use of EV in elderly patients with mUC and highlight the need for further prospective studies in this population.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 10","pages":"4575-4583"},"PeriodicalIF":1.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17803","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Enfortumab vedotin (EV) is an antibody-drug conjugate approved for metastatic urothelial carcinoma (mUC); however, clinical data in elderly patients are limited. Given the increasing use of EV as a first-line or subsequent treatment, assessing its safety and efficacy in older populations is crucial.

Patients and methods: This retrospective, multi-institutional study evaluated the safety and efficacy of EV in patients aged ≥80 years with platinum-refractory mUC. Clinical outcomes were compared with those in patients aged <80 years. Propensity score matching (PSM) was used to minimize selection bias.

Results: Among 129 patients included, 25 (19%) were aged ≥80 years. Median follow-up was 7.7 months. There were no significant differences in overall survival (OS: 14.7 vs. 8.9 months, p=0.411), progression-free survival (PFS: 10.2 vs. 6.5 months, p=0.972), or objective response rate (ORR: 56% vs. 46%, p=0.248) between older and younger patients. Rates of treatment discontinuation and dose reduction were comparable between patients aged ≥80 and those aged <80 years, with no statistically significant differences (8% vs. 13%, p=0.529; 28% vs. 21%, p=0.438).

Conclusion: EV demonstrated comparable efficacy and tolerability in patients aged ≥80 years relative to younger counterparts. These findings support the safe and effective use of EV in elderly patients with mUC and highlight the need for further prospective studies in this population.

查看原文本刊更多论文

老年转移性尿路上皮癌患者使用维多汀治疗的实际疗效。

背景/目的：Enfortumab vedotin （EV）是一种被批准用于转移性尿路上皮癌（mUC）的抗体-药物偶联物；然而，老年患者的临床资料有限。鉴于EV作为一线或后续治疗的使用越来越多，评估其在老年人群中的安全性和有效性至关重要。患者和方法：这项回顾性、多机构研究评估了EV治疗年龄≥80岁铂难治mUC患者的安全性和有效性。结果：纳入的129例患者中，25例（19%）年龄≥80岁。中位随访时间为7.7个月。老年和年轻患者的总生存期（OS: 14.7个月vs. 8.9个月，p=0.411）、无进展生存期（PFS: 10.2个月vs. 6.5个月，p=0.972）或客观缓解率（ORR: 56% vs. 46%, p=0.248）无显著差异。≥80岁患者的停药率和剂量减少率与年龄≥80岁患者的13%相比具有可比性，p=0.529；28% vs. 21%, p=0.438)。结论：与年轻患者相比，EV在≥80岁的患者中表现出相当的疗效和耐受性。这些发现支持在老年mUC患者中安全有效地使用EV，并强调需要在该人群中进行进一步的前瞻性研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.